Latest Ratios: P/E Ratio -1.5x · EV/EBITDA N/A · ROE -68.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $548M | $574M | $1.2B | $1.6B | $1.2B | $2.2B | $1.5B | $843M | $2.1B | $2.7B | $1.8B |
| Enterprise Value | $608M | $634M | $1.3B | $1.6B | $1.3B | $2.0B | $1.7B | $983M | $2.3B | $2.6B | $1.8B |
| P/E Ratio → | -1.48 | — | — | — | — | — | — | — | 459.17 | 20.53 | 80.75 |
| P/S Ratio | 0.66 | 0.70 | 1.48 | 2.10 | 1.72 | 3.12 | 2.65 | 1.32 | 2.48 | 3.48 | 2.30 |
| P/B Ratio | 1.49 | 1.56 | 1.77 | 2.02 | 1.32 | 2.22 | 1.68 | 0.77 | 1.94 | 2.79 | 2.29 |
| P/FCF | — | — | — | — | — | 3588.00 | — | 16.68 | 28.11 | 25.03 | 17.76 |
| P/OCF | 304.42 | 318.77 | — | — | — | 115.74 | — | 13.88 | 25.22 | 23.22 | 16.74 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.77 | 1.53 | 2.13 | 1.85 | 2.88 | 2.96 | 1.54 | 2.65 | 3.35 | 2.30 |
| EV / EBITDA | — | — | — | — | — | — | — | — | 27.94 | 14.96 | 18.16 |
| EV / EBIT | — | — | — | — | — | — | — | — | 187.63 | — | — |
| EV / FCF | — | — | — | — | — | 3311.17 | — | 19.46 | 29.98 | 24.08 | 17.73 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | 69.9% | 68.6% | 70.2% | 71.4% | 68.0% | 70.9% | 76.4% | 77.1% | 77.8% |
| Operating Margin | -8.2% | -8.2% | -14.7% | -34.2% | -20.7% | -27.6% | -35.0% | -36.3% | 0.9% | 15.4% | 6.4% |
| Net Profit Margin | -44.4% | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | -40.2% | -31.2% | 0.5% | 17.0% | 2.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.5% | -68.5% | -17.2% | -31.6% | -12.1% | -2.9% | -22.7% | -18.3% | 0.4% | 15.0% | 2.9% |
| ROA | -42.2% | -42.2% | -11.7% | -22.5% | -8.9% | -2.0% | -15.0% | -12.8% | 0.3% | 10.9% | 2.1% |
| ROIC | -8.7% | -8.7% | -12.0% | -21.7% | -11.9% | -15.4% | -12.8% | -14.1% | 0.5% | 10.9% | 5.1% |
| ROCE | -9.4% | -9.4% | -13.3% | -25.1% | -12.9% | -15.9% | -14.3% | -16.0% | 0.6% | 11.4% | 5.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.57 | 0.57 | 0.20 | 0.19 | 0.16 | 0.10 | 0.33 | 0.21 | 0.21 | 0.01 | 0.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 2.90 | 0.05 | 1.01 |
| Net Debt / Equity | — | 0.16 | 0.05 | 0.03 | 0.10 | -0.17 | 0.20 | 0.13 | 0.13 | -0.11 | -0.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | 1.74 | -0.59 | -0.03 |
| Debt / FCF | — | — | — | — | — | -276.83 | — | 2.78 | 1.87 | -0.95 | -0.03 |
| Interest Coverage | -36.63 | -36.63 | -43.11 | -89.41 | -42.94 | -7.65 | — | -19.68 | 1.00 | 37.09 | 8.23 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | 2.49 | 1.82 | 2.01 | 2.00 | 2.37 | 2.67 | 2.96 | 2.96 | 3.19 | 1.46 |
| Quick Ratio | 2.26 | 2.26 | 1.65 | 1.87 | 1.85 | 2.30 | 2.48 | 2.69 | 2.69 | 2.86 | 1.26 |
| Cash Ratio | 1.12 | 1.12 | 0.62 | 0.90 | 0.84 | 1.66 | 1.03 | 1.16 | 1.16 | 1.77 | 0.69 |
| Asset Turnover | — | 1.17 | 0.82 | 0.66 | 0.57 | 0.52 | 0.39 | 0.41 | 0.54 | 0.66 | 0.63 |
| Inventory Turnover | 8.10 | 8.10 | 9.17 | 10.74 | 10.05 | 12.92 | 6.58 | 5.93 | 6.40 | 5.17 | 4.06 |
| Days Sales Outstanding | — | 51.04 | 52.82 | 55.39 | 54.66 | 48.25 | 58.65 | 79.22 | 59.44 | 48.24 | 52.66 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | 0.2% | 4.9% | 1.2% |
| FCF Yield | — | — | — | — | — | 0.0% | — | 6.0% | 3.6% | 4.0% | 5.6% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 2.4% | 0.0% | 1.8% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 2.4% | 0.0% | 1.8% |
| Shares Outstanding | — | $93M | $91M | $83M | $81M | $78M | $75M | $74M | $76M | $72M | $69M |
Reimbursement and regulatory volatility
Based on current market data, Myriad Genetics trades at a price-to-sales ratio of 0.67, which suggests a significant valuation discount compared to high-growth peers like Natera, reflecting investor skepticism regarding the company's ability to successfully execute its transformation plan and achieve sustainable long-term profitability.
The forward P/E of 95.92 indicates that the market is pricing in a substantial recovery in earnings, yet the lack of a meaningful PEG ratio highlights the difficulty in forecasting growth in a business model currently defined by operational losses. Investors should monitor whether the current valuation floor holds as the company attempts to pivot from legacy diagnostic testing toward higher-margin, integrated mental health solutions.
According to historical financial data, Myriad's ROIC has remained consistently negative, bottoming out at -39.9% in 2025Q2, which indicates that the company is currently destroying shareholder value rather than compounding it through its core diagnostic operations and ongoing laboratory transformation initiatives.
The persistent negative returns on capital suggest that the company's invested capital is not generating sufficient operating income to cover the cost of its asset base. This trend warrants further investigation into whether the current R&D and SG&A spend will eventually yield a competitive moat or if the business model requires a more fundamental restructuring to achieve positive economic value added.
As reported in recent quarterly filings, Myriad's cash conversion cycle has fluctuated around 50 days, a metric that appears to be driven by persistent challenges in DSO and inventory management, suggesting that the company faces structural friction in converting diagnostic test volume into timely cash collections.
The asset turnover ratio, hovering near 0.29, reflects a capital-intensive laboratory model that is not yet operating at optimal capacity. Investors should monitor the DSO trends closely, as any further elongation in collection cycles could signal deteriorating relationships with payers or increased complexity in the reimbursement process for newer genomic tests.
Based on the most recent balance sheet, Myriad maintains a current ratio of 2.40, which appears to provide an adequate short-term liquidity buffer, yet this figure may overstate the company's financial flexibility given the ongoing cash burn and the volatility of its working capital requirements.
While the quick ratio of 2.19 suggests the company can cover immediate liabilities without relying on inventory liquidation, the reliance on external financing to bridge operational gaps remains a concern. The company's liquidity position appears stable for now, but it warrants monitoring as the firm continues to navigate the high costs associated with its transformation plan.
The price-to-sales ratio is the most commonly misapplied metric for Myriad Genetics, as it obscures the significant variance in earnings quality between transactional diagnostic tests and the potentially higher-margin, recurring revenue streams associated with the company's integrated mental health platform.
Relying solely on P/S ignores the impact of variable consideration and the high cost of customer acquisition inherent in the diagnostic sector. Analysts should instead focus on the net cash collected per test and the contribution margin of specific segments to better understand the true earning power of the business model.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MYGN stock.
Myriad Genetics, Inc.'s current P/E ratio is -1.5x. The historical average is 28.9x.
Myriad Genetics, Inc.'s return on equity (ROE) is -68.5%. The historical average is -5.3%.
Based on historical data, Myriad Genetics, Inc. is trading at a P/E of -1.5x. Compare with industry peers and growth rates for a complete picture.
Myriad Genetics, Inc. has 69.9% gross margin and -8.2% operating margin.